00954 CHANGMAO BIO
- 0.445
- 0.0000.00%
CHANGMAO BIO News
Changmao Biotech (00954.HK) received 316,000 H shares from Rui Xinsheng, worth about HK$132,200
On May 7, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 7, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $316,000 at an average price of HK$0.4183 per share on May 6, worth about HK$132,200. After increasing its holdings, Rui Xinsheng's latest shareholding was 12.236 million shares, and the good position ratio rose from 6.49% to 6.66%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals holding 5% or more of the shares
Changmao Biotech (00954.HK) obtained 120,000 H shares from Rui Xinsheng, worth approximately HK$492,000
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $120,000 at an average price of HK$0.41 per share on April 24, worth about HK$492,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 11.92 million shares, and the good position ratio increased from 6.42% to 6.49%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? Major shareholders (individuals and companies holding 5% or more of the shares) as required by the Hong Kong Stock Exchange
Changmao Biotech (00954.HK) received 2.196 million H shares from Rui Xinsheng, worth approximately HK$835,600
On April 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 22, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) $2.196 million at an average price of HK$0.3805 per share on April 19, worth about HK$835,600. After increasing its holdings, Rui Xinsheng's latest shareholding was 11.8 million shares, and the good position ratio increased from 5.23% to 6.42%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (those holding 5% or more of the shares
常茂生物：年報 2023
Changmao Biotech (00954.HK) obtained 80,000 H shares from Rui Xinsheng, worth about HK$32,000
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Rui Xinsheng increased its H share holdings of $80,000 by $Changmao Biotech (00954.HK) at an average price of HK$0.4 per share on April 11, worth about HK$32,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 9.48 million shares, and the good position ratio increased from 5.12% to 5.16%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) must disclose their
Changmao Biotech (00954.HK) received 124,000 H shares from Rui Xinsheng, worth approximately HK$49,900
On April 15, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 15, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $124,000 at an average price of HK$0.4026 per share on April 12, worth about HK$49,900. After the increase in holdings, Rui Xinsheng's latest shareholding was 9.640 million shares, and the good position ratio increased from 5.16% to 5.23%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals holding 5% or more of the shares
Changmao Biotech (00954.HK) obtained 60,000 additional H shares worth HK$23,500 from Rui Xinsheng
On April 8, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 8, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $60,000 at an average price of HK$0.3913 per share on April 5, worth about HK$23,500. After increasing its holdings, Rui Xinsheng's latest shareholding was 9.4 million shares, and the good position ratio increased from 5.08% to 5.12%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their
Changmao Biotech (00954.HK) received 1.98 million shares from Chairman Rui Xinsheng
Gelonghui, April 8 | According to the latest equity disclosure data of the Stock Exchange, from April 2 to April 3, 2024, Changmao Biotech (00954.HK) was granted a total increase of 1.8 million shares by executive director Rui Xinsheng (Chairman) at an average price of HK$0.3796-0.38 per share on the market, involving about HK$750,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 9.34 million shares, and the shareholding ratio increased from 4.01% to 5.08%.
Changmao Biotech (00954.HK) received 1.504 million H shares from Rui Xinsheng, worth about HK$571,500
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) $1,504 million at an average price of HK$0.38 per share on April 2, worth about HK$571,500. After the increase in holdings, Rui Xinsheng's latest shareholding was 8.864 million shares, and the good position ratio increased from 4.01% to 4.83%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares)
Changmao Biotech (00954.HK) received 476,000 H shares from Rui Xinsheng, worth approximately HK$180,700
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Rui Xinsheng increased its holdings of $Changmao Biotech (00954.HK) H shares by 476,000 at an average price of HK$0.3796 per share, worth about HK$180,700. After increasing its holdings, Rui Xinsheng's latest shareholding was 9.34 million shares, and the good position ratio increased from 4.83% to 5.08%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? Major shareholders (individuals and companies holding 5% or more of the shares) as required by the Hong Kong Stock Exchange
Changmao Biotech (00954.HK) obtained 100,000 H shares from Rui Xinsheng, worth about HK$56,000
On April 2, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 2, 2023, Rui Xinsheng increased its holdings of $Changmao Biotech (00954.HK) $100,000 H shares at an average price of HK$0.56 per share, worth about HK$56,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 6.94 million shares, and the good position ratio increased from 3.72% to 3.78%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares
Changmao Biotech (00954.HK) received 420,000 H shares from Rui Xinsheng, worth about HK$163,500
On April 2, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 2, Rui Xinsheng increased its H share holdings of $Changmao Biotech (00954.HK) by $420,000 at an average price of HK$0.3893 per share on March 28, worth about HK$163,500. After increasing its holdings, Rui Xinsheng's latest shareholding was 7.36 million shares, and the good position ratio increased from 3.78% to 4.01%. This transaction involves another related party: Leng Yixin. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) must
Changmao Biotech (00954) announced annual results. Shareholders' losses of 86.057 million yuan were converted from profit to loss year-on-year
Changmao Biotech (00954) announced its annual results for the year ended December 31, 2023. The group received revenue...
CHANGMAO BIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
常茂生物：董事會召開日期
SDIC Securities: The food and beverage industry is resilient and clearly actively recommends companies with changing competitiveness during the off-peak season
China Investment Securities believes that sector valuations are still at the bottom, excellent companies can still have excess profits, and continue to recommend the sector.
Changes in Hong Kong stocks | Changmao Biotech (00954) fell more than 21% last year's pre-loss of more than 85 million yuan, and the company suspended implementation of the proposed A-share issuance plan
Chang Mao Biotech (00954) fell by more than 21%. As of press release, it was down 21.7% to HK$0.415, with a turnover of HK$1.092 million.
Changmao Biochemical Engineering Had Plans to List on Shenzhen Stock Exchange
Changmao Biochemical Engineering Had Plans to List on Shenzhen Stock Exchange
Changmao Biochemical Engineering: Suspending IPO Plan Due to Current Macro Economic Environment
Changmao Biochemical Engineering: Suspending IPO Plan Due to Current Macro Economic Environment
Chang Mao Biotech (00954): Plans to publicly issue RMB common shares and list them on the Shenzhen Stock Exchange GEM have not been implemented
Zhitong Finance App News, Chang Mao Biotech (00954) issued an announcement. As of the date of this announcement, the company's plan to publicly issue RMB common shares (A shares) and list them on the Shenzhen Stock Exchange GEM has not been implemented (recommended plan).
Analysis
Price Target
No Data
